Replies to post #206785 on Biotech Values

[dewophile]

yes but I figured I would post here in case someone did not come across this monograph on twitter
TRIL obviously doesn't have this problem w no RBC binding, but they may find enrollment challenging for AML due to effect on platelets, which as you know are often low in AML too (this was addressed on the cc and the FDA is allowing transfusions to meet the 50K requirement). AML might be a case where more dose work for TRIL would be helpful w gradual titration up in dose based on baseline platelets and also perhaps WBC and ANC